Propolis, as a by-product of honey production, has shown several beneficial effects on cardiovascular risks in past randomised controlled trials, although the findings are not conclusive. In this review, we intend to evaluate the effects of propolis consumption on cardiovascular risk factors by conducting a meta-analysis. The Web of Science, Medline and Scopus databases were comprehensively searched until September 2023. Eligible studies were identified by screening, and their data were extracted. Weighted mean differences with a 95 % CI for each outcome were estimated using the random-effects model. This meta-analysis revealed that propolis consumption led to a significant decrease in the levels of TAG (weighted mean differences (WMD): –10·44 mg/dl 95 % CI: –16·58, –4·31; P = 0·001), LDL-cholesterol (WMD: –9·31 mg/dl; 95 % CI: –13·50, –5·12 mg; P < 0·001), fasting blood glucose (WMD: –7·30 mg/dl; 95 % CI: –11·58, –3·02; P = 0·001), HbA1c (WMD: –0·32 %; 95 % CI: –0·60, –0·05; P = 0·01), insulin (WMD: –1·36 μU/ml; 95 % CI: –2·36, –0·36; P = 0·007), homeostatic model assessment for insulin resistance (WMD: –0·39; 95 % CI: –0·74, –0·03; P = 0·020) and systolic blood pressure (WMD: –2·24 mmHg 95 % CI: –4·08, –0·39; P = 0·010), compared with the control groups. Furthermore, propolis consumption had a significant increasing effect on HDL-cholesterol levels (WMD: 2·03 mg/dl; 95 % CI: 0·24, 3·83; P = 0·020). In contrast, the consumption of propolis had no significant effect on total cholesterol and diastolic blood pressure levels. This systematic review and dose–response meta-analysis suggested that propolis intake may be effective in cardiometabolic improvement in adults. Further, well-designed studies are required to confirm and elucidate all aspects of these findings.